tenofovir alafenamide + lamivudine + efavirenz + rifampicin + isoniazid

This is a combination of three antiretroviral drugs (tenofovir alafenamide, lamivudine, efavirenz) used for HIV treatment and two anti-tuberculosis drugs (rifampicin, isoniazid) used for tuberculosis treatment. This specific 5-drug combination is **not a standard fixed-dose combination product** but represents medications that might be co-administered in patients with HIV-TB coinfection. Significant drug-drug interactions exist between these medications, particularly between rifampicin (an enzyme inducer) and efavirenz (a substrate of those enzymes), which may require dosage adjustments or alternative regimens. Monitoring for hepatotoxicity is also important due to the potential additive effects of isoniazid, rifampicin, and efavirenz.